The researchers have increasingly prescribed the targeted therapies and immunotherapies, but classic chemotherapy agents are still highly used in cancer treatment. Both therapies, the old and the new are associated with cutaneous adverse events (CAEs) that can cause treatment interruptions or reduce patients’ quality of life. An observational, cross‐sectional, single‐center study that included consecutive cancer patients presenting CAEs. The main objective was to describe CAEs derived from antineoplastic drugs. Secondary objectives were to determine the number and severity of CAEs and differences regarding CAEs between conventional chemotherapeutics and targeted therapies.
The researchers included A total of 114 patients in the study with a total number of 177 CAEs. Of the 114 patients, 64 presented a single CAE, 37 patients had two CAEs, and 13 patients presented three CAEs. The most frequent CAEs were pruritus, xerosis, palmar‐plantar erythrodysesthesia, and alopecia. The majority of CAEs were mild, followed by moderate (29.9%) and severe CAEs. Of the 114 patients, 103 received topical agents, and 11 required systemic treatment to manage CAEs. They have found the Prophylactic treatment for CAE delivered to only 4 of 114 patients. They haven’t found any significant differences in the number or severity of CAEs between conventional chemotherapy and targeted therapy.
Ref: https://onlinelibrary.wiley.com/doi/10.1111/ijd.15081
